WindRose Completes Sale of BPD Healthcare to MJH Life Sciences

Strategic Insights -

WindRose Health Investors, the New York-based healthcare private equity firm, has completed the sale of BPD Healthcare to MJH Life Sciences, a leading medical media company in North America. The sale marks a significant moment for BPD, a technology-enabled marketing and communications partner to healthcare systems, care delivery enablers, and healthcare innovators. Over the past three years, BPD strengthened its go-to-market strategy, expanded its technology capabilities, and made several strategic hires to enhance its position as a trusted advisor to healthcare brands. The partnership between WindRose and BPD aimed to provide solutions to the most relevant challenges facing healthcare providers today.

Key Takeaways:

  • WindRose Health Investors completed the sale of BPD Healthcare to MJH Life Sciences, a leading medical media company in North America.
  • BPD Healthcare is a technology-enabled marketing and communications partner to healthcare systems, care delivery enablers, and healthcare innovators.
  • WindRose completed a majority recapitalization of BPD in August 2022.
  • CJ Burnes, Partner at WindRose, praised the partnership, stating, "We're excited to see how the combination with MJH Life Sciences will further accelerate BPD's impact on the broader healthcare industry."
  • Jason Brown, Founder and CEO of BPD, expressed gratitude towards WindRose, saying, "Their support allowed us to go further, faster...by delivering more powerful solutions to our clients."
  • McDermott Will & Schulte acted as legal advisor to WindRose, and Houlihan Lokey and William Blair acted as financial advisors.
  • Day Pitney acted as legal advisor to MJH.

Statistics:

  • BPD Healthcare provides fully integrated solutions, including branding, marketing, communications, and business consulting, which are technology-enabled, AI-infused, and supported by a proprietary data platform.
  • WindRose has over $3.85 billion under management.
  • The sale completes WindRose's investment in BPD Healthcare, which began with a majority recapitalization in August 2022.

Sources:

  • PRNewswire, "WindRose Health Investors Completes Sale of BPD Healthcare to MJH Life Sciences."
  • WindRose Health Investors, "About BPD"
  • WindRose Health Investors, "About WindRose Health Investors"